Thursday, Eli Lilly and Company (NYSE:LLY) released topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. HFpEF accounts for nearly half of all heart failure cases, and in the U.S., almost 60% of those impacted also live with obesity. HFpEF is a condition in which the heart’s left pumping chamber becomes stiff and unable to fill properly. Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure outcomes, assessed as a composite endpoint, ...